However, our previous study revealed that periportal oxLDL contributed to the development of experimental NASH, and that anti-LOX-1 agent blocked TNF-α production by Kupffer cells [19]. The gene discussed is OLR1; the disease is metabolic dysfunction-associated steatohepatitis.